• German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors.

Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, entitled “New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumors)”, will be hosted at the BioMed X Institute in Heidelberg.

The goal of this partnership is to leverage the latest advances in multi-functional biologics, such as bi- and tri-specific antibodies, to develop new therapies that can engage multiple targets simultaneously within the tumor microenvironment. These next-generation therapies aim to overcome the limitations of conventional treatments by leveraging synergistic effects of different antitumor signaling pathways and mechanisms by manipulating proximity of multiple targets.

Call for Research Proposals

The BioMed X Institute and Daiichi Sankyo are inviting proposals from researchers around the world to participate in this ambitious project.

The MTT initiative focuses on the following key research challenges:

• Development of new therapeutic concepts fo…